SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
American Journal of Cardiovascular Drugs · 2024-11 · 24 (6) · 707-718
DOI: 10.1007/s40256-024-00673-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 24.08.2024. Verfasst von David Aristizábal-Colorado und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Universidad Libre, Cali, Colombia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is associated with a heightened risk of cardiovascular and renal complications. While glycemic control remains essential, newer therapeutic options, such as SGLT2 inhibitors, offer additional benefits beyond glucose reduction. This review delves into the mechanisms underlying the cardio-renal protective effects of SGLT2 inhibitors. By inducing relative hypoglycemia, these agents promote ketogenesis, optimize myocardial energy metabolism, and reduce lipotoxicity. Additionally, SGLT2 inhibitors exert renoprotective actions by enhancing renal perfusion, attenuating inflammation, and improving iron metabolism. These pleiotropic effects, including modulation of blood pressure, reduction of uric acid, and improved endothelial function, collectively contribute to the cardiovascular and renal benefits observed with SGLT2 inhibitor therapy. This review will provide clinicians with essential knowledge, understanding, and a clear recollection of this pharmacological group's mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Universidad Libre, Cali, Colombia.
- Internal Medicine Research Group, Universidad Libre, Cali, Colombia.
- Interamerican Society of Cardiology (SIAC), Mexico City, Mexico.
- Faculty of Health, Pontificia Universidad Javeriana, Cali, Colombia.
- Grupo de Investigación en Ciencias Básicas y Clínicas de la Salud, Universidad Javeriana, Cali, Colombia.
- Department of Endocrinology, Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia.
Zitieren
APA
Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W. A., Corredor-Rengifo, D., Rico-Fontalvo, J., Gómez-Mesa, J. E., Duque-Ossman, J. J., & Abreu-Lomba, A. (2024). SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art. American Journal of Cardiovascular Drugs, 24(6), 707-718. https://doi.org/10.1007/s40256-024-00673-1
Vancouver
Aristizábal-Colorado D, Ocampo-Posada M, Rivera-Martínez WA, Corredor-Rengifo D, Rico-Fontalvo J, Gómez-Mesa JE, et al. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art. American Journal of Cardiovascular Drugs. 2024;24(6):707-718. doi:10.1007/s40256-024-00673-1
BibTeX
@article{AristizbalColorado2024,
author = {Aristizábal-Colorado, David and Ocampo-Posada, Martín and Rivera-Martínez, Wilfredo Antonio and Corredor-Rengifo, David and Rico-Fontalvo, Jorge and Gómez-Mesa, Juan Esteban and Duque-Ossman, John Jairo and Abreu-Lomba, Alin},
title = {SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art},
journal = {American Journal of Cardiovascular Drugs},
year = {2024},
volume = {24},
number = {6},
pages = {707--718},
doi = {10.1007/s40256-024-00673-1}
}
EUVIMED